| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.13.150 |
| P698 | PubMed publication ID | 24156321 |
| P50 | author | Filippo de Braud | Q37837953 |
| Elena Verzoni | Q39606195 | ||
| Giuseppe Procopio | Q39606238 | ||
| Paolo Grassi | Q42343466 | ||
| P2093 | author name string | Francesca Fabiani | |
| Isabella Testa | |||
| P2860 | cites work | Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis | Q27026453 |
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival | Q34021957 | ||
| Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. | Q34081620 | ||
| Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report | Q34494117 | ||
| The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma | Q34543752 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer | Q34724614 | ||
| Diabetes and risk of renal cell carcinoma | Q35659887 | ||
| Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis | Q36594084 | ||
| Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial | Q36936936 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials | Q37692420 | ||
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37721064 | ||
| Toxicities of targeted therapy and their management in kidney cancer. | Q37833262 | ||
| The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma | Q39568931 | ||
| Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue | Q40693029 | ||
| Another Step Toward the Cure of Metastatic Renal Cell Carcinoma? | Q42848141 | ||
| An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors | Q42873292 | ||
| Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program | Q42928398 | ||
| Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. | Q43052144 | ||
| Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency | Q43188309 | ||
| Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study. | Q43566220 | ||
| Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome | Q44166101 | ||
| Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells | Q45400740 | ||
| Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma | Q46321994 | ||
| Unusual bevacizumab-related complication of an oral infection | Q46744805 | ||
| Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma | Q47713907 | ||
| Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib. | Q53239141 | ||
| Complete responses in advanced renal cell carcinoma: utopia or real chance? | Q54459220 | ||
| Severe Pazopanib-Induced Hepatotoxicity: Clinical and Histologic Course in Two Patients | Q58074266 | ||
| Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma | Q59152598 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P304 | page(s) | 1599-1607 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity | |
| P478 | volume | 9 |
| Q38963228 | Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies? |
| Q89074133 | Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology |
| Q51349251 | Metastatic process: the seed and the soil from bench to bedside. |
| Q38682520 | Renal Cancer in the Elderly |
| Q89083835 | Toxicity of Cancer Therapies in Older Patients |
Search more.